Update to the Latin American Thoracic Association (ALAT) recommendations on infectious exacerbation of chronic obstructive pulmonary disease;Actualización de las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC

Archivos de Bronconeumologia

Volumn 40, Issue 7, 2004, Pages 315-325

  Luna, J M ^a   Jardim, J R ^a   Lopez H ^a   Luna, C M ^a   Mazzei, J A ^a   Stamboulian, D ^a   Abreu De Oliveira, J C ^a   Pereira, J ^a   Diaz A ^a   Lisboa, C ^a   Saldias F ^a   Maldonado, D ^a   Torres, C ^a   Martinez Selmo S ^a   Miravitlles, M ^a,b   Rodriguez De Castro F ^a   Torres, A ^a   Anzueto, A ^a   Ramirez J ^a   Diaz M ^a   Perez Padilla R ^a   Ramirez A ^a   Sansores, R ^a   Carrasco, I ^a   Matsuno, A ^a   more..

^a Hospital Clínic ^*

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTAXIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; EPIDEMIOLOGICAL DATA; HUMAN; LUNG INFECTION; MEDICAL SOCIETY; PATHOGENESIS; REVIEW; SOUTH AND CENTRAL AMERICA;

EID: 3142671521     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13063227     Document Type: Review

References (92)

1. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre neumonía adquirida en la comunidad. Arch Bronconeumol 2001;37:340-8.
2. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre exacerbación infecciosa de la EPOC. Arch Bronconeumol 2001;37:349-57.
3. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152: S77-S120.
4. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001;163:1730-54.
5. Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 2002;9:191-7.
6. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. ERS consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS). Eur Respir J 1995;8:1398-420.
7. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):4-28.
8. Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, et al. Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001;37:297-316.
9. Balter MS, Hyland RH, Low DE, Renzi PM, Braude AC, Cole PJ, et al. Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians. Can Med Ass J 1994; 151(Suppl):7-23.
10. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
11. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106: 196-204.
12. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997;156:814-8.
13. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9.
14. Menezes AMB, Victoria CG, Rigatto M. Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study. Thorax 1994;49:1217-21.
15. Sansores R, Pérez-Padilla JR. Enfermedad pulmonar obstructiva crónica. Un problema mundial, un enfoque en México. México DF: Piensa Ed., 1997.
16. INEGI, SSA/DGEI. Estadísticas vitales. Mortalidad. Estados Unidos Mexicanos, 1997. México DF: INEGI, SSA/DGEI, 1998.
17. Maldonado D, Bolívar F, Caballero A, Casas A, Roa J, Salgado C. Sociedad Colombiana de Neumología y Cirugía de Tórax Recomendaciones para el diagnóstico y manejo del paciente con enfermedad pulmonar obstructiva crónica (EPOC). Rev Colombe Neumol 1997;9(Supl):1-39.
18. o 12681-CH. Chile. The adult health policy change. Human resources operation division. Country department. Latin America and the Caribbean Region. Document of the World Bank. November 10, 1994.
19. Christopher J, Murray L, López A. Global health statistics. Harvard School of Public Health, editor. Harvard University Press. Maryland: World Health Organization. 1997.
20. Secretaría de Salud. Dirección General de Epidemiología. Instituto Mexicano de Psiquiatría. Encuesta Nacional de las Adicciones, tabaco. México DF: SSA, 1993.
21. o CDC 92-8420, 1992.
22. Farias Alburquerque C, Vega Huaman R, Gamboa Aboado R, Pinillos Ashton L, Diouff MA. Plan nacional para prevención y control del tabaquismo en el Perú 2001-2005. Comisión Multisectorial Permanente de Lucha Antitabáquica-COLAT Perú. Ministerio de Salud. Organización Panamericana de Salud. Lima, 2001.
23. Arango L, Luna J, Martinez G, Flores M. Tabaquismo en Guatemala. Boletin OPS 1990;2:6-9.
24. Carlini EA, Galduróz JC, Noto AR, Nappo SA. I levantamento domiciliar sobre o uso de drogas psicotrópicas no Brasil. CLR Balieiro. Editores Ltda: Sao Paulo, 2002.
25. Ostro B, Sánchez JM, Aranda C, Eskaland G. Air pollution and mortality: results from a study in Santiago, Chile. J Exp Environ Epidemiol 1996;6:97-114.
26. Tashkin DP, Detals R, Simmonds M, Liu H, Coulson AH, Sayre J, et al. The UCLA population studies of chronic obstructive respiratory diseases. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 1994;149:1209-17.
27. Pérez-Padilla R, Regalado J, Vadel S, Pare P, Chapela R, Samons R, et al. Exposure to biomass smoke and chronic airway diseases in Mexican women. Am J Respir Crit Care Med 1996; 154:701-6.
28. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for chronic obstructive airways disease among women. Chest 1996;109:115-9.
29. Luna J, Arango L. Bronquitis crónica secundaria a la exposición al humo de leña. Archivos Unidad Pulmonar. Hospital Roosevelt. Revista de Medicina Interna de Guatemala 1996;3:16-20.
30. Hendrick DJ. Occupation and chronic obstructive pulmonary disease (COPD). Thorax 1996;51:947-55.
31. Shaheen SO, Barker DJP, Shiell AW, Crocker FJ, Wield GA, Holgate ST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994;149:616-9.
32. 1 decline: a study in miners and nonminers. Am J Respir Crit Care Med 1998;157:1390-6.
33. Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997;10:1380-91.
34. Miravitlles M, Vidal R, De Gracia J. Enfisema por déficit de alfa-1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento. Arch Bronconeumol 1992;28:296-302.
35. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL, on behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999;93:173-9.
36. Monsó E, Ruiz J, Rosell A, Monterola J, Fiz J, Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
37. Sethi S, Evans N, Grant BJB, Murphy T. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
38. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
39. Miravitlies M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M, and Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999;116:40-6.
40. Lieberman D, Lieberman D, Shmarkov O, Gelfer Y, Ben-Yaakov M, Lazarovich Z, et al. Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur Respir J 2002;19:392-7.
41. Mogulkoc N, Karakurt S, Isalska B, Bayindir U, Celikel T, Korten V, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999;160:349-53.
42. Richter SS, Brueggemann AB, Huynh HK, Rhomberg PR, Wingert EM, Flamm R, et al. A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. Intern J Antimicrob Agents 1999;13:99-107.
43. Guzmán-Blanco M, Casellas JM, Sader HS. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infect Dis Clin North Am 2000;14:67-81.
44. Soler T, Salamanca L, Arbo G, Molina E. Susceptibilidad in vitro de cepas de Streptococcus pneumoniae aisladas de infecciones de las vías aéreas inferiores en el Instituto Nacional del Tórax (INT). Rev Med Chil 2002;130:304-8.
45. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
46. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999;14:221-9.
47. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT Global Surveillance Study. J Infect 2002;44(Suppl A):3-10.
48. López H, Sader H, Amábile C, Pedreira W, Muñoz Bellido JL, García Rodríguez JA, y Grupo MSP-LA. Actividad in vitro de moxifloxacino frente a patógenos respiratorios en Iberoamérica. Rev Esp Quimioterap 2002;15:325-34.
49. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
50. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975;50;339-44.
51. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-52.
52. MacFarlane JT, Colville A, Guion A, MacFarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993;341:511-4.
53. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. Q J Med 1995;88:61-8.
54. Huchon GJ, Gialdroni-Grassi G, Léophonte P, Manresa F, Schaberg T, Woodhead M. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996;9:1590-5.
55. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD. Factors associated with poor treatment outcome. Chest 2000;117:662-71.
56. Miravitlles M, Murio C, Guerrero T, on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 2001;17:928-33.
57. Miravitlles M. El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica. Med Clin (Barc) 2002;119:304-14.
58. Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121: 1449-55.
59. Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 2003;123:784-91.
60. Murata GH, Gorby MS, Kapsner CO, Chick TW, Halperin AK. A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease. Arch Intern Med 1992;152:82-6.
61. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-800.
62. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8:1333-8.
63. Landbo C, Prescott E, Lange P, Vestbo J, Almidal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-61.
64. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158-64.
65. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL, on behalf of the EOLO Study Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000;67:495-501.
66. Connors AF Jr, Dawson NV, Thomas C, Harrel FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:959-67.
67. Wilson R, Kubin R, Ballin I, Deppermann KM, Bassaris HP, Leophonte P, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
68. Chodosh S, Schreurs A, Siami G, Barkman HW, Anzueto A, Shan M, et al. The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730-8.
69. Soler N, Ewig S, Torres A, Filella X, González J, Xaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
70. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-80.
71. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of suputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
72. Bresser P, Out TA, Van Alphen L, Jansen HM, Lutter R. Airway inflamation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Am J Respir Crit Care Med 2000;162:947-52.
73. Anzueto A, Rizzo JA, Grosman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis 1999;28:1344-5.
74. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-64.
75. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57: 847-52.
76. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5.
77. Stockley RA. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax 1998;53:58-62.
78. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002;20(Suppl 36):9-19.
79. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gros NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
80. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60.
81. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002;359:1648-54.
82. Allegra L, Grassi C, Grossi E, Pozzi E, Blasi F, Frigerio D, et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 1991;45:138-48.
83. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995;273:957-60.
84. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
85. Miravitlles M, Murio C, Guerrero T, Segú JL. Tratamiento de la bronquitis crónica y la EPOC en atención primaria. Arch Bronconeumol 1999;35:173-8.
86. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993;104:254-8.
87. Miravitlles M. Moxifloxacin: an antibiotic designed for use in the community. Eur Respir Rev 2000;10:161-9.
88. Odenholt I, Lowdin E, Cards O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001;45:23-9.
89. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, et al. Telithromycin is as effective as amoxicillin/calvulanate in acute exacerbations of chronic bronchitis. Respir Med 2002;96:862-71.
90. Soler N, Torres A, Ewig S, González J, Celis R, El-Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
91. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999;130:397-403.
92. Centers for Disease Control and Prevention. Prevention of pneumococcal disease. Recommendations of the Advisory Committee of Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-24.